Analyzing Geovax Labs (GOVX) and The Competition
Geovax Labs (OTCMKTS: GOVX) is one of 32 public companies in the “Commercial physical research” industry, but how does it contrast to its peers? We will compare Geovax Labs to similar companies based on the strength of its dividends, institutional ownership, profitability, analyst recommendations, risk, valuation and earnings.
This is a summary of recent recommendations and price targets for Geovax Labs and its peers, as provided by MarketBeat.com.
|Sell Ratings||Hold Ratings||Buy Ratings||Strong Buy Ratings||Rating Score|
|Geovax Labs Competitors||125||593||1370||55||2.63|
Volatility & Risk
Geovax Labs has a beta of 0.1, suggesting that its stock price is 90% less volatile than the S&P 500. Comparatively, Geovax Labs’ peers have a beta of 4.22, suggesting that their average stock price is 322% more volatile than the S&P 500.
This table compares Geovax Labs and its peers’ net margins, return on equity and return on assets.
|Net Margins||Return on Equity||Return on Assets|
|Geovax Labs Competitors||-303.61%||-211.37%||-45.39%|
Institutional & Insider Ownership
0.1% of Geovax Labs shares are owned by institutional investors. Comparatively, 45.1% of shares of all “Commercial physical research” companies are owned by institutional investors. 2.1% of Geovax Labs shares are owned by insiders. Comparatively, 17.1% of shares of all “Commercial physical research” companies are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.
Earnings & Valuation
This table compares Geovax Labs and its peers revenue, earnings per share and valuation.
|Gross Revenue||Net Income||Price/Earnings Ratio|
|Geovax Labs||$1.08 million||-$2.17 million||-0.92|
|Geovax Labs Competitors||$968.26 million||$63.67 million||12.24|
Geovax Labs’ peers have higher revenue and earnings than Geovax Labs. Geovax Labs is trading at a lower price-to-earnings ratio than its peers, indicating that it is currently more affordable than other companies in its industry.
Geovax Labs peers beat Geovax Labs on 8 of the 10 factors compared.
About Geovax Labs
GeoVax Labs, Inc., a clinical-stage biotechnology company, develops human vaccines for infectious diseases and cancer in the United States and internationally. The company through its patented Modified Vaccinia Ankara-Virus Like Particle vaccine platform develops various vaccines. It is developing various vaccines that are in human clinical trials, and preclinical research and development phases, including vaccines against human immunodeficiency virus (HIV); Zika virus; malaria; and hemorrhagic fever viruses, such as Ebola, Sudan, Marburg, and Lassa, as well as therapeutic vaccines for chronic Hepatitis B infections and cancers. The company has collaboration and partnership agreements with the National Institute of Allergy and Infectious Diseases of the National Institutes of Health; the HIV Vaccines Trial Network; Centers for Disease Control and Prevention; United States Army Research Institute of Infectious Disease; U.S. Naval Research Laboratory; Emory University; University of Pittsburgh; Georgia State University Research Foundation; Peking University; University of Texas Medical Branch; the Institute of Human Virology at the University of Maryland; the Scripps Research Institute; the Burnet Institute; American Gene Technologies, Inc.; Viamune, Inc.; Vaxeal Holding SA; and CaroGen Corporation. GeoVax Labs, Inc. was founded in 2001 and is based in Smyrna, Georgia.
Receive News & Ratings for Geovax Labs Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Geovax Labs and related companies with MarketBeat.com's FREE daily email newsletter.